According to a market report by Lucintel, the future of the erythropoietin drug market in United States looks promising with opportunities in the applications. The erythropoietin drug market in United States is expected to reach an estimated $7.1 billion by 2031 with a CAGR of 1.8% from 2025 to 2031. The major drivers for this market are the increasing day by day cases of chronic disease and the growing number of CKD cases.
A more than 150-page report to understand trends, opportunity and forecast in erythropoietin drug market in United States to 2031 by type (biologic and biosimilar), product (erythropoietin and darbepoetin-alfa), and application (cancer, renal disease, neurology, and others).
Download sample by clicking on erythropoietin drug market in United States
Lucintel forecasts that, within the type category, biologic will remain the larger segment over the forecast period.
Within the application category, renal disease will remain the largest segment.
This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at [email protected] To get access of more than 1000 reports at fraction of cost visit Lucintel's Analytics Dashboard.
About Lucintel
At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: [email protected]
Tel. +1-972-636-5056
Explore Our Latest Publications
Erythropoietin Drug Market in Australia
Erythropoietin Drug Market in Brazil
Erythropoietin Drug Market in Canada
Erythropoietin Drug Market in Mexico
Erythropoietin Drug Market in Saudi Arabia
Erythropoietin Drug Market in South Africa